期刊
WOMENS HEALTH
卷 2, 期 5, 页码 733-741出版社
SAGE PUBLICATIONS LTD
DOI: 10.2217/17455057.2.5.733
关键词
anastrozole; aromatase inhibitors; breast cancer; exemestane; prevention; raloxifene; Selective estrogen receptor modulators; tamoxifen
资金
- AstraZeneca and Aventis
- statistical consultant for AstraZeneca
- Lilly
- Pfizer
Trials with tamoxifen have clearly shown that estrogen receptor-positive breast cancer risk can be reduced at a late stage in the natural history with prophylactic agents. Approximately half of the cases were prevented. The current challenge is to achieve this or better efficacy, and to reduce side effects. A recent trial found that the selective estrogen receptor modulator raloxifene has similar efficacy to tamoxifen but fewer side effects. Long-term Phase III trials are currently underway studying two aromatase inhibitors. Results from other studies suggest that these agents have a better side-effect profile and may prevent 70-80% of receptor-positive breast cancers. New agents are needed for receptor-negative breast cancer and several possibilities are currently under investigation.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据